LAURUS LABS Share price

The Company was originally incorporated as Laurus Labs Private Limited on September 19 2005 at Hyderabad Andhra Pradesh India as a private limited company under the Companies Act 1956. The Company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited and a fresh certificate of incorporation consequent upon change of name on conversion to a public limited company was issued by the RoC on February 12 2007. Subsequently the name of the Company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the Company with Aptuit Singapore and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on July 19 2007. Thereafter the Company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited and a fresh certificate of incorporation consequent upon change of name on conversion to a private limited company was issued by the RoC on July 24 2007. Subsequently the name of the Company was changed to Laurus Labs Private Limited consequent to the proposed dilution of the shareholding of Aptuit Singapore in the Company and a fresh certificate of incorporation consequent upon change of name was issued by the RoC on February 21 2012. The Company was converted into a public limited company and the name of the Company was changed to Laurus Labs Limited. A fresh certificate of incorporation consequent upon change of name on conversion to a public limited company was issued by the RoC on August 16 2016.Major events and milestones of the Company :2006- Set up the R&D Centre- Signed term sheet with a leading Indian pharmaceutical company for oncology APIs- Filed the first patent application2007- Set up Unit 1- Investment by Aptuit Singapore of Rs.1.02 billion in the Company- Executed manufacturing and services agreements with three multinational companies- Commenced operations at the R&D Centre2008- Filed first Drug Master File- Commenced operations at Unit 1- Supplied the Company’s first product to the USA2009- DSIR recognition received for the R&D Centre- Commercialised four nutritional fine chemicals- Launched the Company’s first product in Europe- Entered into a license agreement with an international organization and a multinational company for license to manufacture and sell one of the products in the ARV segment2010- Received US FDA certification TGA and UK MHRA certification for the Unit 12011- Received US FDA certification for the R&D Centre- Received Korean FDA certification for Unit 1 and the R&D Centre2012- Investment of Rs.490 million in the Company by FIL Capital Management and FIP through primary investment and secondary acquisition of Aptuit’s majority stake in the Company along with additional investments by one of the Promoters2013- Crossed Rs.10 billion of revenues- Received WHO approval for Unit 1- Purchased/ leased land at Visakhapatnam for future expansion2014- Purchased approximately 135 acres of land at Visakhapatnam for future expansion- Investment of Rs.3000 million by Bluewater and acquisition by Bluewater of significant stake from FIL Capital Management and FIP (acting through FIL Capital Advisors) through secondary share purchase transaction- Commenced construction of Unit 2- Incorporated Laurus Inc. at Delaware as a wholly owned subsidiary of the Company2015- Commenced commercial operations at Unit 3- Acquired 27% stake in Sriam Labs- Successful inspection by WHO NIP Hungary and US FDA for Unit 1 and Unit 3 manufacturing sites2016- Successful US FDA inspection of the kilo lab facility at R&D Hyderabad- Received approval from BfraM Germany for Unit 2- Crossed Rs.15 billion in revenues- Filed first ANDA with the US FDA and first dossier with the WHO- Acquired balance 73% stake in Sriam Labs making it a wholly owned subsidiary of the CompanyAwards and Accreditations :2012- Script Award for the “Best Company in an Emerging Market”- FAPCCI (The Federation of Andhra Pradesh Chambers of Commerce and Industry) Award for “Outstanding Export Performance” (Silver Rolling Trophy)- “Outstanding Exports Performance Award” - Bulk Drugs (medium) - Gold by Pharmaceuticals Export Promotion Council of India (“PHARMEXCIL”)2013- Outstanding Exports Performance Award – Bulk Drugs - Silver by PHARMEXCIL- Silver Certificate of Merit at the Economic Times India Manufacturing Excellence Awards 20132014- Vishwakarma Rashtriya Puraskar and National Safety Award for Unit 1 presented by the Ministry of Labour and Employment Government of India for the performance year 2012- Outstanding Exports Performance Award- Bulk Drugs (Mid Range) by PHARMEXCIL- Silver Certificate of Merit at the Economic Times India Manufacturing Excellence Awards 2014- ‘Excellence in Performance & Business Scalability (Large Companies)’ award in the Business Today-YES Bank Emerging Companies Excellence Awards2015- The Company was featured as one of the 13 Hidden Gems in India by Forbes India and the CEO was featured on its cover page- ‘Health Care Company of the Year 2015’ award by VC Circle- Silver Certificate of Merit at the India Manufacturing Excellence Awards 2015- ‘Best Visualised App Delivery Implementation’ award from Citrix- Certificate of achievement in the Business Leader 2015 Award for excellence in the pharmaceuticals sector2016- National Safety Award (runner-up) for Unit 1 presented by the Ministry of Labour and Employment Government of India for the performance year 2014.